Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death

V. W.Y. Lui, E. Y.L. Wong, K. Ho, P. K.S. Ng, C. P.Y. Lau, S. K.W. Tsui, C. M. Tsang, S. W. Tsao, S. H. Cheng, M. H.L. Ng, Y. K. Ng, E. K.Y. Lam, B. Hong, K. W. Lo, T. S.K. Mok, A. T.C. Chan, Gordon Mills

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

c-Met represents an important emerging therapeutic target in cancer. In this study, we demonstrate the mechanism by which c-Met tyrosine kinase inhibition inhibits tumor growth in a highly invasive Asian-prevalent head and neck cancer, nasopharyngeal cancer (NPC). c-Met tyrosine kinase inhibitors (TKIs; AM7 and c-Met TKI tool compound SU11274) downregulated c-Met phosphorylation, resulting in marked inhibition of NPC cell growth and invasion. Strikingly, inhibition of c-Met resulted in significant downregulation of TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) and subsequent depletion of intracellular NADPH. Importantly, overexpression of TIGAR ameliorated the effects of c-Met kinase inhibition, confirming the importance of TIGAR downregulation in the growth inhibitory activity of c-Met TKI. The effects of c-Met inhibition on TIGAR and NADPH levels were observed with two different c-Met TKIs (AM7 and SU11274) and with multiple cell lines. As NADPH provides a crucial reducing power required for cell survival and proliferation, our findings reveal a novel mechanistic action of c-Met TKI, which may represent a key effect of c-Met kinase inhibition. Our data provide the first evidence linking c-Met, TIGAR and NADPH regulation in human cancer cells suggesting that inhibition of a tyrosine kinase/TIGAR/NADPH cascade may have therapeutic applicability in human cancers.

Original languageEnglish (US)
Pages (from-to)1127-1134
Number of pages8
JournalOncogene
Volume30
Issue number9
DOIs
StatePublished - Mar 3 2011
Externally publishedYes

Fingerprint

Glycolysis
NADP
Cell Death
Down-Regulation
Apoptosis
Protein-Tyrosine Kinases
Nasopharyngeal Neoplasms
Neoplasms
Phosphotransferases
Growth
Head and Neck Neoplasms
Cell Survival
Phosphorylation
Cell Proliferation
Cell Line
Therapeutics

Keywords

  • c-Met tyrosine kinase inhibitor
  • NADPH
  • TIGAR

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Lui, V. W. Y., Wong, E. Y. L., Ho, K., Ng, P. K. S., Lau, C. P. Y., Tsui, S. K. W., ... Mills, G. (2011). Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene, 30(9), 1127-1134. https://doi.org/10.1038/onc.2010.490

Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. / Lui, V. W.Y.; Wong, E. Y.L.; Ho, K.; Ng, P. K.S.; Lau, C. P.Y.; Tsui, S. K.W.; Tsang, C. M.; Tsao, S. W.; Cheng, S. H.; Ng, M. H.L.; Ng, Y. K.; Lam, E. K.Y.; Hong, B.; Lo, K. W.; Mok, T. S.K.; Chan, A. T.C.; Mills, Gordon.

In: Oncogene, Vol. 30, No. 9, 03.03.2011, p. 1127-1134.

Research output: Contribution to journalArticle

Lui, VWY, Wong, EYL, Ho, K, Ng, PKS, Lau, CPY, Tsui, SKW, Tsang, CM, Tsao, SW, Cheng, SH, Ng, MHL, Ng, YK, Lam, EKY, Hong, B, Lo, KW, Mok, TSK, Chan, ATC & Mills, G 2011, 'Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death', Oncogene, vol. 30, no. 9, pp. 1127-1134. https://doi.org/10.1038/onc.2010.490
Lui, V. W.Y. ; Wong, E. Y.L. ; Ho, K. ; Ng, P. K.S. ; Lau, C. P.Y. ; Tsui, S. K.W. ; Tsang, C. M. ; Tsao, S. W. ; Cheng, S. H. ; Ng, M. H.L. ; Ng, Y. K. ; Lam, E. K.Y. ; Hong, B. ; Lo, K. W. ; Mok, T. S.K. ; Chan, A. T.C. ; Mills, Gordon. / Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. In: Oncogene. 2011 ; Vol. 30, No. 9. pp. 1127-1134.
@article{a0e91bcf027149b180ca4557a2059abe,
title = "Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death",
abstract = "c-Met represents an important emerging therapeutic target in cancer. In this study, we demonstrate the mechanism by which c-Met tyrosine kinase inhibition inhibits tumor growth in a highly invasive Asian-prevalent head and neck cancer, nasopharyngeal cancer (NPC). c-Met tyrosine kinase inhibitors (TKIs; AM7 and c-Met TKI tool compound SU11274) downregulated c-Met phosphorylation, resulting in marked inhibition of NPC cell growth and invasion. Strikingly, inhibition of c-Met resulted in significant downregulation of TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) and subsequent depletion of intracellular NADPH. Importantly, overexpression of TIGAR ameliorated the effects of c-Met kinase inhibition, confirming the importance of TIGAR downregulation in the growth inhibitory activity of c-Met TKI. The effects of c-Met inhibition on TIGAR and NADPH levels were observed with two different c-Met TKIs (AM7 and SU11274) and with multiple cell lines. As NADPH provides a crucial reducing power required for cell survival and proliferation, our findings reveal a novel mechanistic action of c-Met TKI, which may represent a key effect of c-Met kinase inhibition. Our data provide the first evidence linking c-Met, TIGAR and NADPH regulation in human cancer cells suggesting that inhibition of a tyrosine kinase/TIGAR/NADPH cascade may have therapeutic applicability in human cancers.",
keywords = "c-Met tyrosine kinase inhibitor, NADPH, TIGAR",
author = "Lui, {V. W.Y.} and Wong, {E. Y.L.} and K. Ho and Ng, {P. K.S.} and Lau, {C. P.Y.} and Tsui, {S. K.W.} and Tsang, {C. M.} and Tsao, {S. W.} and Cheng, {S. H.} and Ng, {M. H.L.} and Ng, {Y. K.} and Lam, {E. K.Y.} and B. Hong and Lo, {K. W.} and Mok, {T. S.K.} and Chan, {A. T.C.} and Gordon Mills",
year = "2011",
month = "3",
day = "3",
doi = "10.1038/onc.2010.490",
language = "English (US)",
volume = "30",
pages = "1127--1134",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death

AU - Lui, V. W.Y.

AU - Wong, E. Y.L.

AU - Ho, K.

AU - Ng, P. K.S.

AU - Lau, C. P.Y.

AU - Tsui, S. K.W.

AU - Tsang, C. M.

AU - Tsao, S. W.

AU - Cheng, S. H.

AU - Ng, M. H.L.

AU - Ng, Y. K.

AU - Lam, E. K.Y.

AU - Hong, B.

AU - Lo, K. W.

AU - Mok, T. S.K.

AU - Chan, A. T.C.

AU - Mills, Gordon

PY - 2011/3/3

Y1 - 2011/3/3

N2 - c-Met represents an important emerging therapeutic target in cancer. In this study, we demonstrate the mechanism by which c-Met tyrosine kinase inhibition inhibits tumor growth in a highly invasive Asian-prevalent head and neck cancer, nasopharyngeal cancer (NPC). c-Met tyrosine kinase inhibitors (TKIs; AM7 and c-Met TKI tool compound SU11274) downregulated c-Met phosphorylation, resulting in marked inhibition of NPC cell growth and invasion. Strikingly, inhibition of c-Met resulted in significant downregulation of TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) and subsequent depletion of intracellular NADPH. Importantly, overexpression of TIGAR ameliorated the effects of c-Met kinase inhibition, confirming the importance of TIGAR downregulation in the growth inhibitory activity of c-Met TKI. The effects of c-Met inhibition on TIGAR and NADPH levels were observed with two different c-Met TKIs (AM7 and SU11274) and with multiple cell lines. As NADPH provides a crucial reducing power required for cell survival and proliferation, our findings reveal a novel mechanistic action of c-Met TKI, which may represent a key effect of c-Met kinase inhibition. Our data provide the first evidence linking c-Met, TIGAR and NADPH regulation in human cancer cells suggesting that inhibition of a tyrosine kinase/TIGAR/NADPH cascade may have therapeutic applicability in human cancers.

AB - c-Met represents an important emerging therapeutic target in cancer. In this study, we demonstrate the mechanism by which c-Met tyrosine kinase inhibition inhibits tumor growth in a highly invasive Asian-prevalent head and neck cancer, nasopharyngeal cancer (NPC). c-Met tyrosine kinase inhibitors (TKIs; AM7 and c-Met TKI tool compound SU11274) downregulated c-Met phosphorylation, resulting in marked inhibition of NPC cell growth and invasion. Strikingly, inhibition of c-Met resulted in significant downregulation of TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) and subsequent depletion of intracellular NADPH. Importantly, overexpression of TIGAR ameliorated the effects of c-Met kinase inhibition, confirming the importance of TIGAR downregulation in the growth inhibitory activity of c-Met TKI. The effects of c-Met inhibition on TIGAR and NADPH levels were observed with two different c-Met TKIs (AM7 and SU11274) and with multiple cell lines. As NADPH provides a crucial reducing power required for cell survival and proliferation, our findings reveal a novel mechanistic action of c-Met TKI, which may represent a key effect of c-Met kinase inhibition. Our data provide the first evidence linking c-Met, TIGAR and NADPH regulation in human cancer cells suggesting that inhibition of a tyrosine kinase/TIGAR/NADPH cascade may have therapeutic applicability in human cancers.

KW - c-Met tyrosine kinase inhibitor

KW - NADPH

KW - TIGAR

UR - http://www.scopus.com/inward/record.url?scp=79952283136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952283136&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.490

DO - 10.1038/onc.2010.490

M3 - Article

VL - 30

SP - 1127

EP - 1134

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 9

ER -